SLC5A2 and type 2 diabetes mellitus: Gliflozins are a class of drugs with SGLT2 inhibitory properties primarily applied for glycemic control [11], with beneficial effects in patients with cardiovascular diseases and T2D, as well as cardiovascular complications [12, 13].